

Cleveland State University

EngagedScholarship@CSU

---

Undergraduate Research Posters 2015

Undergraduate Research Posters

---

2015

## Mechanism of action by which 5-NIdR acts as a therapeutic agent against brain cancer


Seol Kim

*Cleveland State University*

Jung-Suk Choi

*Cleveland State University*

Follow this and additional works at: [https://engagedscholarship.csuohio.edu/u\\_poster\\_2015](https://engagedscholarship.csuohio.edu/u_poster_2015)

 Part of the [Life Sciences Commons](#), [Medicine and Health Sciences Commons](#), and the [Physical Sciences and Mathematics Commons](#)

[How does access to this work benefit you? Let us know!](#)

---

### Recommended Citation

Kim, Seol and Choi, Jung-Suk, "Mechanism of action by which 5-NIdR acts as a therapeutic agent against brain cancer" (2015). *Undergraduate Research Posters 2015*. 20.

[https://engagedscholarship.csuohio.edu/u\\_poster\\_2015/20](https://engagedscholarship.csuohio.edu/u_poster_2015/20)

This Book is brought to you for free and open access by the Undergraduate Research Posters at EngagedScholarship@CSU. It has been accepted for inclusion in Undergraduate Research Posters 2015 by an authorized administrator of EngagedScholarship@CSU. For more information, please contact [library.es@csuohio.edu](mailto:library.es@csuohio.edu).



## ***Mechanism of action by which 5-NIdR acts as a therapeutic agent against brain cancer***

College of Sciences and Health Professions

**Student Researchers:** Seol Kim, <sup>1</sup>Jung-Suk Choi

**Faculty Advisor:** Anthony J. Berdis

### **Abstract**

Approximately 10,000 people in the United States are diagnosed annually with a brain tumor. In addition, the prognosis for brain cancer patients is poor as these cancers have low survival rates of less than 10%. One important chemotherapeutic agent used to treat brain cancer is temozolomide, an alkylating agent that causes cell death by damaging DNA. In this project, we tested the ability of a specific non-natural nucleoside developed in our lab, designated 5-NIdR, to increase the efficacy of temozolomide against brain cancer. Animal studies using xenograft mice were performed to evaluate the *in vivo* efficacy of this drug combination against brain cancer. Results indicate that treatment with 5-NIdR does not affect the rate of tumor growth compared to treatment with vehicle control. While treatment with temozolomide slows the rate of tumor growth by 2-fold, more striking results are obtained when 5-NIdR is combined with temozolomide as this drug combination causes complete tumor regression within two weeks of treatment. To better define the cellular mechanism for this effect, a series of cell-based studies were performed to compare the cytotoxic effects of temozolomide alone and in combination with 5-NIdR. Flow cytometry experiments measuring Annexin V staining as a marker for apoptosis demonstrate that cells treated with 5-NIdR and temozolomide accumulate show significantly higher levels of apoptosis compared to cells treated with 5-NIdR or temozolomide alone. Experiments measuring cell-cycle progression demonstrate that treatment with 5-NIdR and temozolomide causes cancer cells to accumulate at S-phase before undergoing apoptosis. The block at S-phase likely results from the ability of 5-NIdR to inhibit the replication of damaged DNA created by temozolomide. Consistent with this mechanism, significantly higher levels of single- and double-strand DNA breaks are detected in cancer cells treated with 5-NIdR and temozolomide compared to cells treated individually with either agent. Collectively, these studies provide additional pharmacological evidence for combining 5-NIdR and temozolomide as a possible treatment strategy to effectively treat brain cancers.

<sup>1</sup>Post-doctoral Fellow